Universal Ibogaine has announced the appointment of a new CEO: Dr. Rami Batal. Batal is a veteran biopharmaceutical industry executive and a healthcare professional with impressive expertise and a background in mental health, specifically substance use disorders. Batal has spent his career in biomedical innovation, specifically biopharmaceutical research, development and commercialization of medicines for pain and central nervous system disorders (“CNS”). He has worked with numerous multinational pharmaceutical companies and biotech startups, including, most recently, Antibe Therapeutics (TSX:ATE), where he oversaw the commercial readiness of otenaproxesul, a phase 3 pain/osteoarthritis drug candidate, which was recently outlicensed to Nuance Pharma for the Greater China region. Prior to his time at Antibe, Batal served as vice president of medical innovation and vice president of medical research of Canopy Growth Corporation. He also cofounded CHI (“CHI”), a biotech company focused on cannabinoid research for biopharmaceutical purposes. Batal earned his doctorate in experimental medicine from McGill University and is licensed to practice pharmacy in Quebec. “Rami’s past experience in biopharmaceutical research, particularly in CNS, is exactly the leadership UI needs to advance our planned clinical research program with Health Canada for the use of ibogaine in addiction treatment, which is an integral part of our overall strategy to address the global and devastating opioid addiction crisis,” said Universal Ibogaine executive chairman Shayne Nyquvest in the press release.
To view the full press release, visit https://ibn.fm/fM4xA
About Universal Ibogaine Inc.
Universal Ibogaine is a privately held company formed in 2018 and based in Vancouver, British Columbia. UI is in the initial stages of implementing and financing its business plan, which aims at developing a global network of addiction treatment clinics and introducing ibogaine in a medical setting where authorized, for the interruption and ideally cessation of addiction to opioids, as well as other substances of abuse, such as alcohol and cocaine. For more information about the company, please visit www.IbogaineInc.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.